uniQure stock holds recent gains as Huntington’s gene therapy filing reshapes outlook

uniQure N.V. stock (ISIN IL0011559904) is trading near USD 44.00 on Nasdaq as of September 18, 2026, roughly 84 percent above its level at the start of the year and supported by growing optimism around its Huntington’s disease gene therapy program.

Huntington’s gene therapy filing sets the tone

The central catalyst for uniQure stock in September 2026 is the company’s recent submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for its investigational Huntington’s disease gene therapy ifezuntirgene inilparvovec, also known as AMT-130. According to MarketBeat, uniQure announced the BLA submission on September 2, 2026, positioning AMT-130 as one of the first gene therapies seeking approval for this rare neurodegenerative disorder.

Coverage compiled by MarketBeat shows that multiple outlets reported on September 2, 2026 that uniQure filed for Huntington’s disease approval in the United States and pursued parallel submissions in the United Kingdom, with several analysts calling eventual FDA acceptance of the BLA the next major share-price catalyst. For investors, this regulatory step is critical because it opens the door to potential commercial revenue from AMT-130 if the product ultimately gains approval.

Share performance and valuation context

The recent regulatory momentum comes against the backdrop of a sharp share-price recovery in 2026. As of the latest data snapshot cited by MarketBeat, uniQure shares closed at USD 44.00 on Nasdaq on September 18, 2026, down 0.20 percent on the day, but well above the USD 23.93 level at the beginning of 2026. This implies a year-to-date gain of 83.9 percent, underlining how strongly the stock has re-rated as confidence in the company’s pipeline has improved.

The same overview indicates that the company’s market capitalization stands around USD 3.1 billion as of early July 2026, a figure highlighted again in a comparative analysis published by the American Association of Individual Investors. According to AAII on July 1, 2026, uniQure’s market capitalization at that time was USD 3.1 billion, versus a biotechnology sector median of USD 294.0 million, underscoring that the company is already a mid-cap player within its industry.

Latest reported financials frame risk and opportunity

In parallel with the BLA filing, uniQure has continued to report its financial results for 2026. The company announced its second quarter 2026 figures in late July 2026. According to StockTitan, uniQure released its second quarter 2026 financial results and provided a broader company update on July 29, 2026, covering performance for the quarter ended June 30, 2026. While detailed line items for revenue and earnings are not fully visible in the brief overview, the filing is described as a standard quarterly earnings report, indicating that investors now have a current snapshot of operating trends within the last nine months.

The same StockTitan listing shows that the second quarter 2026 results announcement on July 29, 2026 was accompanied by a Form 10-Q quarterly report, underlining that the disclosed numbers were part of uniQure’s regular Securities and Exchange Commission reporting cycle. For investors, these filings provide necessary context for assessing how quickly the company’s expenses related to clinical development and commercialization might shift once AMT-130 moves closer to market.

Analyst views highlight valuation tensions

Analyst commentary collected in recent weeks points to a mixed but generally cautious view of uniQure’s valuation. The AAII comparison between uniQure and Viridian Therapeutics shows that, as of July 1, 2026, uniQure had a Value Score of 1, categorized as Ultra Expensive relative to peers, alongside a Growth Score of 4 and an Earnings Estimate Revisions Score of 35. According to AAII, uniQure’s stock was up 75.1 percent for the year at that point, down 14.7 percent over the previous five trading days, and up 224.03 percent over the past year, illustrating both strong long-term performance and short-term volatility.

For retail investors, the combination of an Ultra Expensive value score and robust price gains means that expectations for AMT-130 and other pipeline assets are already embedded in the share price. If subsequent clinical or regulatory developments fall short of these expectations, the stock could be vulnerable to pullbacks. Conversely, a positive regulatory outcome and clarity on pricing and reimbursement for Huntington’s disease gene therapy could justify the current premium valuation.

Upcoming dates and what to watch next

Looking ahead, uniQure’s second quarter 2026 earnings release on July 29, 2026 marked the most recent reported financial period within the nine-month freshness window leading up to September 20, 2026. According to StockTitan, the company scheduled its Q2 2026 earnings call for July 29, 2026 at 8:30 a.m. Eastern Time, and the financial calendar listing confirms this as the latest completed quarterly event. As of September 20, 2026, market participants therefore focus primarily on regulatory milestones around the AMT-130 BLA and potential updates to guidance rather than an imminent earnings release.

Beyond Huntington’s disease, uniQure continues to advance other gene therapy candidates, but the near-term share-price sensitivity is largely tied to regulatory news flow for AMT-130. Any indication of FDA acceptance timelines, advisory committee scheduling or feedback from European regulators could quickly influence the stock, given its already elevated valuation and strong year-to-date performance.

Stock level and investor takeaway

At a closing price of USD 44.00 on Nasdaq on September 18, 2026, uniQure stock remains near the upper end of its trading range for the year and roughly 84 percent above its January 2026 starting level, with a market capitalization of around USD 3.1 billion in early July 2026. The combination of strong price gains, an Ultra Expensive value score and a high-stakes Huntington’s disease gene therapy filing means that future regulatory decisions are likely to be the main driver of returns for holders of uniQure shares.

More news and analyses on uniQure stock